Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.
📚 期刊: Circulation
📅 发表: 0000-00-00
🔬 PMID: 42137960 👁️ 浏览: 11
👤 作者: Vega, O'Mahony, Barbour, Yu, Knöchel, Brengdahl, Hochdörfer, Bergenholm, Töppner Carlsson, Ahnmark, Underwood, Rudvik, Carter, Laru, Gutgsell, Twaddle, Garkaviy, Bogstedt, Hurt-Camejo, Miliotis, Ryaboshapkina, Hober, Hubbard, Serrano-Wu, Kaushik, Geschwindner, McCarthy, Lindén, Rosenmeier
心血管
📝 摘要
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk. Current PCSK9 inhibitors are injectable therapies; no oral small-molecule PCSK9 inhibitor has yet been approved.